forecast

Worst Outcome Is Fast Approval Without Surveillance

The current FDA regime accepts accelerated approval based on small patient samples in exchange for post-market surveillance to catch harms afterward, but the worst of all worlds—and Gawande's fear—is speeding drugs through while gutting the surveillance and withdrawal capability, which is exactly where drug-maker incentives point and where the public stops paying attention; underinvestment in surveillance and disasters like Vioxx illustrate the danger.

forecastpending

Speaker

Atul Gawande

Evidence Quote

“all of the incentives are from the drug-maker point of view. And then, when the public’s not paying attention, that’s where we start dialing back.”

Source

Atul Gawande— Conversations with Tyler
Created: 6/12/2026, 4:55:15 PM

Your notes

Loading notes...